The tariff classification of Rituximab (CAS-174722-31-7) from Spain
Issued March 18, 2003 by U.S. Customs and Border Protection.
Tariff classification
HTS codes: 3002.10.0190
Headings: 3002
Product description
The subject product [nonproprietary (USAN) name and international nonproprietary name (INN): Rituximab, brand name: Rituxan®] is a genetically engineered monoclonal antibody. It is indicated for the treatment of patients with relapsed or refractory, low-grade follicular, CD20-positive, B-cell non-Hodgkin’s lymphoma. Although you opine that the subject product is classified under subheading 3002.90.5150, HTS, we note that, pursuant to Note 2 to Chapter 30, HTS, and Explanatory Note 30.02(C)(2), HTS, monoclonal antibodies are considered to be “modified immunological products,” for tariff purposes. As such, they fall within subheading 3002.10.01, HTS, which lists, inter alia, “[m]odified immunological products,” by name.
CBP rationale
The applicable subheading for Rituximab will be 3002.10.0190, Harmonized Tariff Schedule of the United States (HTS), which provides for “Antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes: Other.
Full text
NY J83358 March 18, 2003 CLA-2-30:RR:NC:2:238 J83358 CATEGORY: Classification TARIFF NO.: 3002.10.0190 Ms. Tracey L. Hess Unitrans International Corporation 461 Littlefield Avenue South San Francisco, CA 94080-6106 RE: The tariff classification of Rituximab (CAS-174722-31-7) from Spain Dear Ms. Hess: In your letter dated March 5, 2003, on behalf of Genentech, Inc., you requested a tariff classification ruling. The subject product [nonproprietary (USAN) name and international nonproprietary name (INN): Rituximab, brand name: Rituxan®] is a genetically engineered monoclonal antibody. It is indicated for the treatment of patients with relapsed or refractory, low-grade follicular, CD20-positive, B-cell non-Hodgkin’s lymphoma. Although you opine that the subject product is classified under subheading 3002.90.5150, HTS, we note that, pursuant to Note 2 to Chapter 30, HTS, and Explanatory Note 30.02(C)(2), HTS, monoclonal antibodies are considered to be “modified immunological products,” for tariff purposes. As such, they fall within subheading 3002.10.01, HTS, which lists, inter alia, “[m]odified immunological products,” by name. The applicable subheading for Rituximab will be 3002.10.0190, Harmonized Tariff Schedule of the United States (HTS), which provides for “Antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes: Other.” The rate of duty will be free. This merchandise may be subject to the requirements of the Federal Food, Drug, and Cosmetic Act, which is administered by the U.S. Food and Drug Administration. You may contact them at 5600 Fishers Lane, Rockville, Maryland 20857, telephone number 301-443-1544. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 646-733-3033. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of AGN-150998 from Germany
The tariff classification of Cervimax™ IHC Monoclonal Antibody Kit from Italy
The tariff classification of various Influenza Reagents from Great Britain
The tariff classification of various Roche laboratory reagents as calibrators and controls for clinical chemistry analyzers
The tariff classification of Laboratory Reagents for Detecting Dengue Virus Antibodies in Human Serum from Thailand
The tariff classification of AGN-150894 Anticalins from Germany
The tariff classification of samples of human serum from France
The tariff classification of monoclonal antibodies in bulk and measured dosage forms, from England, Ireland, and Germany
The tariff classification of Rabbit Antibody Serum and Chicken Antibody IgY from China
The tariff classification of a solid phase enzyme-linked immunosorbent assay (ELISA) for the estimation of rat or mouse Glutathione S-Transferases in biological fluids, in kit form, from Ireland
Searching CBP rulings the smart way
TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.
Book a demo →